Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment

Within the tumor microenvironment, cancer-associated fibroblasts stand out—not just by number but by influence. Though often seen as support players, they actively shape how tumors advance, spread, and even resist treatment. Their behavior emerges through crosstalk with malignant cells and surrounding tissue elements.

New tools like single-cell sequencing have revealed diversity where once uniformity was assumed. Different subsets now appear—some fueling growth, others restraining it.

---

What Are Cancer-Associated Fibroblasts (CAFs)?

Within tumor environments, cancer-associated fibroblasts exist as diverse groups of active stromal cells. Unlike normal fibroblasts, they remain persistently activated, showing:

• Rapid division
• Increased production of structural proteins
• Continuous signaling activity
• Resistance to apoptosis

These cells:

• Remodel the extracellular matrix
• Promote angiogenesis
• Alter immune responses
• Influence tumor metabolism

In cancers like pancreatic ductal adenocarcinoma, CAFs may make up up to 80% of tumor mass, contributing to tumor stiffness.

---

Origins and Sources of Cancer-Associated Fibroblasts

Cellular Origins of CAFs

CAFs arise from multiple sources:

• Resident fibroblasts activated by tumor signals
• Mesenchymal stem cells (MSCs) from bone marrow
• Adipocytes (fat cells), especially in breast/ovarian cancers
• Endothelial cells via EndMT
• Epithelial cells via EMT
• Pericytes via PDGF-BB signaling
• Stellate cells (liver, pancreas)

---

How CAFs Are Generated

Key signaling pathways include:

• TGF-β → drives activation (α-SMA expression)
• IL-6 / JAK-STAT → inflammatory CAFs (iCAFs)
• PDGF signaling → proliferation and migration
• Notch signaling & tumor exosomes
• Hypoxia, ECM stiffness, oxidative stress

---

CAF Heterogeneity and Classification

Phenotypic Markers

Common markers (not exclusive):

• α-SMA
• FAP
• Vimentin
• FSP1/S100A4
• PDGFRα/β

Subtype-specific markers:

• myCAFs → α-SMA, TAGLN
• iCAFs → IL-6, CXCL12
• apCAFs → MHC-II genes (HLA-DRA, CD74)
• Stemness CAFs → CD10, GPR77
• Immunotherapy-resistant CAFs → LRRC15

---

Functional Classification

Three major CAF types:

1. Myofibroblastic CAFs (myCAFs)

• High α-SMA
• ECM production
• Increase tissue stiffness
• Limit drug penetration

2. Inflammatory CAFs (iCAFs)

• Secrete IL-6, IL-8, LIF
• Promote inflammation
• Modify immune responses

3. Antigen-Presenting CAFs (apCAFs)

• Express MHC-II
• Suppress immune activation

A 2025 study also identified:

• proCAF
• iCAF
• myCAF
• matCAF (linked to poor prognosis)

---

Role of CAFs in Tumor Progression

Tumor Growth

CAFs promote growth by:

• Secreting growth factors (HGF, FGF, IGF)
• Activating PI3K/AKT and MAPK pathways
• Remodeling ECM
• Producing MMPs for invasion

They also support tumors metabolically via the reverse Warburg effect.

---

Metastasis

CAFs assist cancer spread by:

• Inducing EMT via TGF-β and HGF
• Preparing pre-metastatic niches
• Traveling with tumor cells
• Transferring signals via exosomes

---

Drug Resistance

CAFs contribute to resistance by:

• Creating physical drug barriers
• Activating survival pathways (IL-6 → STAT3)
• Maintaining cancer stem cells
• Blocking immunotherapy responses

---

Angiogenesis

CAFs stimulate blood vessel formation through:

• VEGF
• PDGF-C
• FGF-2
• Angiopoietins

They also stabilize vessels and alter oxygen levels.

---

CAFs and Tumor Immunity

Immunosuppressive Functions

CAFs:

• Block T-cell infiltration (CXCL12)
• Recruit Tregs, MDSCs, M2 macrophages
• Express PD-L1/PD-L2
• Suppress NK and dendritic cells

---

Immunoactivating CAFs

Some CAF subsets enhance immunity:

• CD146+ CAFs → better outcomes
• CCL19+ CAFs → T-cell recruitment

---

Targeting CAFs for Therapy

Inhibition Strategies

• FAP-targeted therapies (CAR-T, antibodies)
• TGF-β inhibitors
• Hedgehog pathway inhibitors

---

Reprogramming CAFs

• Vitamin D analogs (calcipotriol)
• Retinoic acid (ATRA)
• JAK inhibitors

---

Clinical Trials

Examples include:

• FAP-targeted immunotherapy (NCT03386721)
• IL-2 + PD-1 therapy (NCT03875079)
• Defactinib + pembrolizumab
• Tocilizumab (IL-6 blockade)

---

Research Technologies

Modern tools include:

• Single-cell RNA sequencing
• Spatial transcriptomics
• Organoids and co-culture systems
• CRISPR mouse models
• AI-based data analysis

---

Challenges in CAF Research

• Lack of specific markers
• Inconsistent classification
• Functional duality (pro- and anti-tumor)
• Cellular plasticity
• Risk of targeting beneficial CAFs

---

Future Directions

• Precision targeting of CAF subtypes
• Combination therapies (CAF + immunotherapy)
• Spatial multi-omics
• FAP-based theranostics

---

Conclusion

Cancer-associated fibroblasts are central players in tumor biology. They influence:

• Tumor growth
• Metastasis
• Immune response
• Treatment resistance

Their diversity makes them both a challenge and an opportunity. Future therapies may focus not just on destroying tumors, but on reprogramming the tumor microenvironment itself.